Skill Checkup: A 44-Year-Old Man With Moderate to Severe Lower Back Pain Despite Treatment

Marina Magrey, MD


April 05, 2023

According to the ASAS/EULAR guidelines, the patient's response to third-line treatment, in this case with a second TNF inhibitor, should be assessed after at least 12 weeks of therapy. The decision to continue therapy is based on evidence of substantially decreased disease activity (ie, improvement in ASDAS ≥ 1.1) and the clinician's opinion.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.